Provided by Tiger Trade Technology Pte. Ltd.

Celldex Therapeutics

40.57
+0.19000.47%
Post-market: 40.570.00000.00%16:20 EDT
Volume:416.89K
Turnover:16.90M
Market Cap:3.18B
PE:-9.35
High:40.98
Open:40.16
Low:39.53
Close:40.38
52wk High:45.14
52wk Low:21.34
Shares:78.49M
Float Shares:73.02M
Volume Ratio:0.43
T/O Rate:0.57%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.3401
EPS(LYR):-3.9000
ROE:-43.88%
ROA:-27.62%
PB:4.46
PE(LYR):-10.40

Loading ...

Celldex Therapeutics (CLDX) Enters Russell Growth Indexes As Barzolvolimab Data Puts Valuation In Focus

Simply Wall St.
·
Jul 02

Celldex Therapeutics Shareholders Approve 3,400,000-share Increase to 2021 Equity Plan at Annual Meeting

Reuters
·
Jun 26

Celldex Therapeutics (CLDX) Stock Could Be 61% Below Fair Value After New Trial Data

Simply Wall St.
·
Jun 20

QURE Was Just the Beginning: 5 Biotech Catalysts I’m Watching Now

InvestorPlace
·
Jun 19

Why Celldex Therapeutics (CLDX) Is Up 12.2% After CSU Drug Data Suggest Disease Modification Potential

Simply Wall St.
·
Jun 18

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Jun 15

Celldex Therapeutics Price Target Maintained With a $42.00/Share by HC Wainwright & Co.

Dow Jones
·
Jun 15

Celldex presents long-term results from Phase 2 study of barzolvolimab

TIPRANKS
·
Jun 15

Celldex presents first-in-human results for CDX-622

TIPRANKS
·
Jun 15

Celldex Therapeutics Says Barzolvolimab Meets Primary Efficacy Endpoint In Phase 2 CSU Study

Reuters
·
Jun 14

Celldex says Phase 2 barzolvolimab data show sustained off-treatment angioedema improvement in CSU patients

Reuters
·
Jun 14

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained off-Treatment Improvement in Angioedema in Patients With Csu at the European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 14

Celldex Therapeutics - Barzolvolimab Meets Primary Efficacy Endpoint in Phase 2 Csu Study

THOMSON REUTERS
·
Jun 14

Celldex reports positive Phase 1 results for bispecific antibody CDX-622 in healthy participants

Reuters
·
Jun 14

Celldex Presents Positive First-in-Human Results From Phase 1 Study of Novel Bispecific Cdx-622 at the European Academy of Allergy and Clinical Immunology Annual Meeting

THOMSON REUTERS
·
Jun 14

Celldex to present barzolvolimab, CDX-622 data at EAACI annual congress

Reuters
·
Jun 11

Celldex Announces Multiple Upcoming Presentations from Leading Mast Cell Targeting Pipeline at the Upcoming 2026 European Academy of Allergy and Clinical Immunology Annual Congress

GlobeNewswire
·
Jun 11

Celldex Therapeutics Is Maintained at Buy by UBS

Dow Jones
·
Jun 11

UBS Adjusts Price Target on Celldex Therapeutics to $45 From $38, Maintains Buy Rating

MT Newswires Live
·
Jun 10

Celldex price target raised to $45 from $38 at UBS

TIPRANKS
·
Jun 10